SNIPER (ABL) -019

SNIPER (ABL) -019, conjugating Dasatinib (ABL inhibitor) to MV-1 (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 0.3 μM[1].

Product Specifications

UNSPSC

12352005

Target

Bcr-Abl; SNIPERs

Type

Reference compound

Related Pathways

PROTAC; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/sniper-abl-019.html

Solubility

10 mM in DMSO

Smiles

CC1=C(NC(C2=CN=C(NC3=CC(N4CCN(C(COCCOCCOCCNC([C@H](C(C5=CC=CC=C5)C6=CC=CC=C6)NC([C@H]7N(C([C@@H](NC([C@H](C)NC)=O)C8CCCCC8)=O)CCC7)=O)=O)=O)CC4)=NC(C)=N3)S2)=O)C(Cl)=CC=C1

Molecular Formula

C60H77ClN12O9S

Molecular Weight

1177.85

References & Citations

[1]Shibata N, et al. Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands. Cancer Sci. 2017 Aug;108 (8) :1657-1666.